subject
total
adult
volunt
charlottesvil
virginia
area
neutral
antibodi
titer
rhinoviru
type
enrol
studi
subject
requir
free
cold
symptom
fever
week
prior
enter
trial
histori
hypersensit
antihistamin
addit
subject
exclud
histori
allerg
rhiniti
bronchial
asthma
lower
respiratori
tract
diseas
chronic
obstruct
lung
diseas
emphysema
subject
histori
alcohol
drug
abus
exclud
volunt
use
investig
drug
within
day
antihistamin
andor
cold
prepar
within
day
monoamin
oxidas
inhibitor
within
day
astemizol
within
day
medic
thought
interfer
studi
drug
exclus
criteria
includ
pregnanc
lactat
glaucoma
renal
hepat
endocrin
digest
genitourinari
neurolog
psycholog
diseas
protocol
review
human
investig
committe
univers
virginia
studi
medic
loratadin
administ
tablet
placebo
tablet
ident
loratadin
tablet
contain
pharmacolog
inert
ingredi
viru
challeng
intranas
challeng
rhinoviru
type
perform
coars
drop
use
ml
ml
per
nostril
inoculum
pool
contain
tissu
cultur
infect
dose
viru
challeng
perform
twice
interv
challeng
inoculum
pool
safeti
test
extran
agent
measur
infect
nasal
wash
collect
day
prior
immedi
inocul
challeng
viru
determin
whether
subject
infect
wildtyp
viru
viru
challeng
nasal
wash
collect
morn
administr
medic
wash
cultur
rhinoviru
day
challeng
human
embryon
lung
cell
isol
identifi
rhinoviru
type
neutral
typespecif
antibodi
venou
blood
obtain
day
prior
treatment
day
intranas
inocul
measur
homotyp
neutral
antibodi
measur
ill
presenc
sever
symptom
determin
daili
begin
first
day
treatment
day
prior
viral
challeng
total
day
data
symptom
collect
immedi
administr
loratadin
placebo
nurs
record
subject
assess
sever
symptom
prior
h
scale
none
mild
moder
sever
sever
symptom
assess
sneez
runni
nose
nasal
obstruct
sore
throat
cough
headach
malais
chilli
total
symptom
score
determin
ad
sever
score
symptom
period
viral
challeng
score
symptom
present
immedi
challeng
subtract
daili
score
symptom
evalu
ill
sever
also
includ
daili
measur
nasal
secret
weight
subject
kept
daili
log
number
cough
sneez
nasal
secret
measur
cough
sneez
count
start
subject
cloister
hotel
challeng
occur
leav
hotel
last
day
subject
ask
whether
opinion
experienc
cold
inform
occurr
sever
advers
effect
collect
daili
grade
none
mild
moder
sever
experiment
design
trial
singlecent
random
doubleblind
placebocontrol
parallel
group
studi
healthi
volunt
year
age
either
sex
loratadin
placebo
administ
morn
day
studi
viral
challeng
given
day
subject
randomli
assign
receiv
either
treatment
placebo
blind
treatment
statu
observ
record
clinic
inform
data
analysi
compar
proport
fisher
exact
test
use
test
use
compar
ordin
interv
data
result
probabl
test
subject
subject
enrol
receiv
loratadin
receiv
placebo
four
subject
loratadin
group
placebo
group
infect
wildstrain
rhinoviru
time
entri
studi
exclud
evalu
subject
placebo
discontinu
medic
develop
migrain
headach
day
leav
evalu
subject
analysi
infect
rate
twentyeight
subject
loratadin
subject
placebo
shed
challeng
viru
nasal
fluid
day
p
tabl
mean
number
day
viru
shed
similar
challeng
volunt
infect
volunt
group
homotyp
antibodi
respons
occur
subject
treat
loratadin
subject
receiv
placebo
infect
rate
viral
shed
andor
antibodi
rise
loratadin
group
placebo
group
p
viral
titer
geometr
mean
viral
titer
peak
second
day
viral
challeng
expect
figur
viral
titer
similar
group
although
trend
lower
titer
placebo
group
day
occurr
ill
twentythre
infect
subject
loratadin
infect
subject
placebo
met
modifi
jackson
criteria
ill
p
symptom
score
mean
sneez
sever
score
similar
first
day
tend
lower
placebo
group
fourth
day
figur
mean
total
symptom
score
similar
group
figur
rhinorrhea
score
tend
lower
placebo
group
day
revers
seen
day
figur
mean
nasal
obstruct
sore
throat
cough
score
similar
group
figur
figur
figur
mean
headach
malais
score
tend
lower
loratadin
group
latter
day
ill
figur
figur
nasal
mucu
weight
consist
trend
nasal
secret
weight
lower
placebo
group
figur
total
mean
se
nasal
mucu
weight
day
g
loratadin
group
g
placebo
group
p
level
mean
nasal
fluid
level
rose
baselin
day
peak
day
level
similar
group
figur
advers
event
one
subject
placebo
group
migrain
headach
vomit
anoth
vomit
otherwis
advers
event
report
regard
origin
purpos
studi
differ
observ
group
receiv
loratadin
group
receiv
placebo
viral
shed
rate
viral
titer
overal
infect
rate
ill
rate
symptom
score
level
nasal
secret
group
also
similar
result
also
show
therapeut
effect
loratadin
sneez
support
earlier
work
patient
natur
cold
secondgener
antihistamin
ineffect
reduc
sneez
firstgener
antihistamin
effect
reduc
sneez
cold
secondgener
antihistamin
interest
firstgener
antihistamin
besid
abil
block
also
block
muscarin
receptor
pass
bloodbrain
barrier
secondgener
antihistamin
specif
blocker
without
recogn
pharmacolog
properti
pass
bloodbrain
barrier
inform
neurolog
pathway
sneez
reflex
come
mainli
work
anim
sneez
reflex
travel
along
peripher
nerv
medulla
oblongata
neuropharmacolog
sneez
involv
muscarin
nicotin
receptor
cold
sneez
reflex
begin
nose
infect
nasal
cell
cold
viru
figur
evid
activ
basophil
mast
cell
releas
histamin
occur
cold
howev
presum
stimul
free
nerv
end
ethmoid
branch
trigemin
nerv
inflammatori
mediat
known
present
bradykinin
nerv
impuls
travel
along
affer
nerv
fiber
sensori
trigemin
nucleu
medulla
oblongata
arriv
adjac
sneez
center
via
anoth
synaps
impuls
arriv
parasympathet
superior
salivari
nucleu
facial
nerv
cross
synaps
travel
via
preganglion
fiber
greater
petros
nerv
sphenopalatin
ganglion
support
rout
transmiss
sneez
find
inject
alcohol
sphenopalatin
ganglion
block
sneez
reflex
impuls
travel
across
anoth
synaps
mainli
nicotin
muscarin
proce
via
postganglion
fiber
synaps
muscarin
mucu
gland
blood
vessel
stimul
result
glandular
secret
vascular
transud
restimul
free
nerv
end
trigemin
nerv
pathway
impuls
redirect
trigemin
nucleu
subsequ
sneez
center
medulla
restimul
sneez
center
suffici
impuls
direct
intramedullari
fiber
synaps
multipl
respiratori
center
reticular
format
synaps
respiratori
neuron
vagu
phrenic
intercost
nerv
via
nicotin
synaps
nerv
impuls
stimul
muscular
contract
respons
sneez
nose
first
site
histamin
may
involv
pathogenesi
sneez
antihistamin
might
inhibit
sneez
reflex
present
free
nerv
end
trigemin
nerv
possibl
nasal
mucosa
primari
site
action
firstgener
antihistamin
find
histamin
level
found
elev
nasal
secret
cold
also
earlier
natur
cold
studi
current
studi
secondgener
antihistamin
despit
reach
nasal
mucosa
despit
activ
ineffect
sneez
reduct
howev
nasal
mucosa
appear
enhanc
sensit
histamin
cold
role
nasal
site
entir
exclud
next
possibl
site
firstgener
antihistamin
block
sneez
medulla
oblongata
synapt
junction
present
sever
locat
muscarin
receptor
identifi
certain
area
brain
receptor
would
potenti
target
action
firstgener
secondgener
antihistamin
howev
synapt
mediat
involv
sneez
reflex
medulla
character
observ
failur
secondgener
antihistamin
reduc
sneez
cold
support
possibl
site
import
muscarin
activ
exclus
respons
parasympathet
stimul
glandular
secret
vascular
dilat
transud
occur
next
anticholinerg
activ
firstgener
antihistamin
would
expect
oper
site
support
welldocu
effect
firstgener
antihistamin
reduc
volum
nasal
fluid
product
cold
second
affer
impuls
medulla
initi
stimul
free
nerv
end
trigemin
nerv
vascular
transud
lead
releas
kininogen
result
gener
kinin
event
provid
mean
direct
stimul
free
nerv
end
kinin
well
histamin
releas
mast
cell
kinin
stimul
provid
anoth
possibl
target
action
antihistamin
also
nerv
impuls
redirect
medulla
muscarin
synapt
site
may
block
firstgener
antihistamin
describ
point
motor
neuron
becom
involv
nerv
transmiss
depend
nicotinerg
receptor
thu
would
suscept
action
antihistamin
analysi
suggest
import
site
therapeut
effect
firstgener
antihistamin
sneez
medulla
oblongata
muscarin
receptor
may
involv
receptor
known
present
high
concentr
hypothalamu
histamin
act
neurotransmitt
help
regul
level
wake
account
drowsi
associ
use
firstgener
antihistamin
dens
concentr
receptor
hypothalamu
parasympathet
nerv
fiber
aris
activ
hypothalamu
probabl
histamin
play
role
signal
transmiss
region
firstgener
antihistamin
also
known
help
reduc
nausea
associ
motion
sick
scopolamin
anticholinerg
drug
pass
bloodbrain
barrier
effect
treatment
motion
sick
wherea
atropin
pass
bloodbrain
barrier
readili
effect
antinausea
effect
scopolamin
depend
partial
block
muscarin
receptor
vestibular
nuclei
area
postrema
brain
nuclei
brainstem
may
use
muscarin
receptor
system
well
support
idea
muscarin
receptor
cn
part
sneez
reflex
present
inform
complet
medullari
synaps
neurotransmitt
involv
sneez
reflex
work
need
area
howev
avail
inform
suggest
effect
treatment
sneez
cold
requir
compound
pass
bloodbrain
barrier
possess
muscarinicblock
activ
